Article Information
History
- May 17, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- 1Laboratory of Systems Pharmacology and the Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA
- 2Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School and MIT, Cambridge, Massachusetts, USA
- 3Dana-Farber Cancer Institute, Boston, Massachusetts, USA
- 4Foundation Medicine Inc., Cambridge, Massachusetts, USA
- 5Department of Pharmacology, Computational Medicine Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
- ↵*These authors contributed equally. To whom correspondence should be addressed: palmer{at}unc.edu; peter_sorger{at}hms.harvard.edu (cc: sorger_admin{at}hms.harvard.edu)
Posted May 17, 2021.
Cancer patient survival can be accurately parameterized, revealing time-dependent therapeutic effects and doubling the precision of small trials
